News

Vertex plan to build on pain drug breakthrough hits hurdles
The drugmaker shed billions of dollars in value after it told investors that widening Journavx’s approval to chronic pain ...
Vertex Announces Marketing Authorization in Canada for ALYFTREK, a Once-Daily Next-Generation CFTR Modulator for the Treatment of Cystic Fibrosis
- Approximately 3,800 people in Canada are now eligible for ALYFTREK, with up to 60 people potentially eligible for a medicine that treats the underlying cause of their disease for the first time - ...